Just as F1 teams rely on real-time data to optimize performance, IoT is enabling life sciences manufacturers to achieve new ...

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

An Oakland financier, which sponsored a life sciences-focused blank-check company this summer that grossed $230 million, ...

Utah's life sciences sector is a significant economic powerhouse, but the misguided the Medication Affordability and Patent ...

Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his ...

Former Fed chairman Alan Greenspan coined the phrase "irrational exuberance" to describe the risk of unduly escalated asset ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne ...

By engaging with some of the most influential executives in the industry and the many organizations that advocate for them, the series will provide valuable perspectives on the evolving landscape of ...